Tevimbra (tislelizumab-jsgr)

Tevimbra (tislelizumab-jsgr)

General Description:
Tevimbra (tislelizumab-jsgr) is a prescription intravenous therapy used for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC). It is also indicated in combination with chemotherapy for adults with non-small cell lung cancer (NSCLC). Tevimbra works by targeting immune checkpoints, enabling the body’s immune system to recognize and attack cancer cells, which helps slow tumor growth and disease progression.

Tevimbra is administered intravenously under the supervision of a healthcare professional, with dosing schedules determined by your oncologist based on your medical condition and treatment plan.

---

Getting Tevimbra (tislelizumab-jsgr) in India
Tevimbra is approved in the United States (FDA), European Union (EMA), and the United Kingdom (MHRA), among other countries. While not yet commercially available in India, eligible patients may access Tevimbra through a Named Patient Program (NPP) with physician supervision.

MitoGENE assists Indian patients in obtaining Tevimbra safely and compliantly, handling all documentation, import approvals, and logistics according to India’s regulatory framework.

If you or a loved one has advanced ESCC or NSCLC, MitoGENE ensures a secure, patient-centric process to access Tevimbra (tislelizumab-jsgr). Our team provides guidance on eligibility, documentation, import approvals, and coordinated delivery, ensuring safe and timely access to this therapy.

---

Medicine Approved By:
• Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Medicines and Healthcare Products Regulatory Agency (MHRA, UK)

---

Available Dosage Form & Package:
• Single-dose vial: 100 mg/10 mL (10 mg/mL)

---